Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

Kidney cancer study reveals new findings about MiTF family gene mutations

A new study from clinicians and researchers at the University of Michigan Rogel Cancer Center, U-M Department of Pathology and the Michigan Center for Translational Pathology reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.

14 Aug 2023

Pioneering study links testicular cancer among military personnel to ‘forever chemicals’

Gary Flook served in the Air Force for 37 years, as a firefighter at the now-closed Chanute Air Force Base in Illinois and the former Grissom Air Force Base in Indiana, where he regularly trained with aqueous film forming foam, or AFFF — a frothy white fire retardant that is highly effective but now known to be toxic.

9 Aug 2023

UCLA researchers confirm mutations that predispose patients to rare kidney cancer syndrome

Researchers at the UCLA Jonsson Comprehensive Cancer Center have confirmed that a large number of genetic variants of unknown significance are in fact verified mutations that predispose patients to a rare hereditary syndrome that increases the risk of kidney cancer.

13 Jul 2023

Adolescent and young adult kidney cancer survivors at elevated risk for heart problems

New research out of VCU Massey Cancer Center indicates that many adolescent and young adult kidney cancer survivors are at a significantly elevated risk for heart issues.

5 Jul 2023

New kidney cancer model highlights molecular targets and genomic events that drive metastasis

Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression.

26 Jun 2023

Study finds new way to predict therapy response in metastatic renal cell carcinoma

Dr. Niklas Klümper, resident at the Department of Urology and Pediatric Urology of the University Hospital Bonn (UKB) and working group leader at the Institute for Experimental Oncology (IEO), and Dr. Jonas Saal, resident at the Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology of the UKB, demonstrated a significant improvement in predicting the response to therapy in metastatic renal cell carcinoma by incorporating the level of inflammation, which was assessed using two straightforward blood parameters, alongside the conventional imaging-based approach.

22 Jun 2023

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment.

5 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

26 May 2023

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology's annual meeting.

23 May 2023

Metabolically healthy and unhealthy 'forms' of obesity linked with increased risk of obesity-related cancers

New research to be presented at this coming week's European Congress on Obesity in Dublin, Ireland (17-20 May) and published in the Journal of the National Cancer Institute shows that both the metabolically healthy and unhealthy 'forms' of obesity are associated with an increased risk of various obesity-related cancers, with the relationship stronger in metabolically unhealthy obesity.

15 May 2023

Obesity has been significantly underestimated as risk factor for colorectal cancer, scientists say

Obesity is a known risk factor for colorectal cancer. Scientists at the German Cancer Research Center (DKFZ) have now shown that this association has probably been significantly underestimated so far.

5 May 2023

Houston-based cancer survivor donates $10 million to accelerate translational research and clinical trials

Vijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.

20 Apr 2023

Changes to tumor DNA can help predict cancer's next move

Knowing whether a tumor might grow or spread to other parts of a patient’s body could be key to survival – and now scientists are one step closer to unlocking the ability to predict just that.

13 Apr 2023

Combinatorial biomarker predicts response to immunotherapy in kidney cancer patients

The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict — before treatment begins — how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

Connection between mitochondrial metabolite and activation of inflammatory response revealed

A new study shows for the first time a connection between a mitochondrial metabolite and the activation of an inflammatory response.

8 Mar 2023

Even small bouts of exercise protective against heart disease, cancer

In a recent article published in the British Journal of Sports Medicine, researchers explored the relationship between non-occupational physical activity (PA) levels and poor cardiovascular diseases (CVDs) and cancer outcomes, including mortality.

5 Mar 2023

Predicting the likelihood of kidney cancer recurrence by looking at DNA mutations

A decade-long international study into kidney cancer has shown that doctors can predict the likelihood of a patient's disease returning by looking at DNA mutations in their tumors.

24 Feb 2023

DNA sequencing may help predict a patient’s risk of kidney cancer recurrence

Studying the mutations in kidney cancer after surgery could help to better predict the risk of the disease coming back, according to the latest results of a decade-long international study.

23 Feb 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023